Previous 10 | Next 10 |
Shares of Altamira Therapeutics (CYTO) are up 27% in premarket trading after the U.S. FDA granted 510(k) clearance to market nasal spray Bentrio for allergic rhinitis. Bentrio is a drug-free products that forms a thin layer on the n nasal mucosa to prevent allergens from coming on c...
Company gains access to the world's largest OTC market for consumer health products Expects substantial and growing US Bentrio revenue contribution over next couple of years HAMILTON, BERMUDA / ACCESSWIRE / June 27, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedic...
Commercial-stage pharma Altamira Therapeutics (NASDAQ:CYTO) added ~8% in the pre-market Thursday after the company announced that its clinical trial designed to evaluate Bentrio nasal spray in COVID-19 met the enrollment target ahead of the schedule. The randomized, placebo controll...
Reached targeted clinical trial enrollment of 136 subjects ahead of schedule At current patient enrollment, top-line data read-out is expected in Q3-22 HAMILTON, BERMUDA / ACCESSWIRE / June 23, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing the...
Altamira Therapeutics (NASDAQ:CYTO) on Monday announced what it deemed to be positive data from its phase 2 trial evaluating its nasal spray treatment AM-125 for acute vertigo. Data from the mid-stage trial, called TRAVERS, showed a significant improvement in balance in patients with acute ve...
Significant improvement in balance after four-week treatment with AM-125 20 mg nasal spray vs. placebo Study provides proof-of-concept for enhancement and acceleration of vestibular recovery Treatment well-tolerated by study participants and safe Company plans a US FDA IND fi...
Altamira Therapeutics (NASDAQ:CYTO) on Thursday said that on June 2 it had got a notification from Nasdaq that the company was not in compliance with listing rules on minimum bid price requirement. The notice said that the minimum bid price per share for the company's common shares was b...
HAMILTON, BERMUDA / ACCESSWIRE / June 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that on June 02, 2022 the Company received a letter from the Listings Qualifications Department...
Altamira (NASDAQ:CYTO) on Wednesday announced positive data from trial testing Bentrio for protection in human rhinovirus (HRV) infection. Bentrio is a drug-free nasal spray developed and commercialized by the Company's unit Altamira Medica for protection against airborne viruses an...
Altamira Therapeutics (NASDAQ:CYTO) announced positive outcomes from testing Bentrio for protection in human rhinovirus (or HRV) infection. Bentrio is a drug-free nasal spray developed and commercialized by the company's affiliate Altamira Medica for protection against airborne...
News, Short Squeeze, Breakout and More Instantly...
Altamira Therapeutics Ltd. Company Name:
CYTO Stock Symbol:
NASDAQ Market:
Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications HAMILTON, BERMUDA / May 1, 2024 / Altamira Therapeutics Ltd. (“Altamira” or t...
Hamilton, Bermuda, April 24, 2024 (GLOBE NEWSWIRE) -- Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published in Allergy journal Study met primary efficacy endpoint of improvement in nasal symptoms (p = 0.013) Corroborated ...
Hamilton, Bermuda, April 10, 2024 (GLOBE NEWSWIRE) -- Management to host conference call today, April 10, at 8.30 a.m. EDT RNA delivery business progressing with new collaborations, potential new applications Partnering of legacy assets underway as Company transitions to f...